Meta AnalysisID 4046
利血平是否确实导致抑郁？一项系统评价
CRD42021225227
To evaluate the effects of the anti-hypertensive medication reserpine on depressive symptoms across human studies by synthesising the evidence from all studies assessing a reserpine-treated condition and an untreated con
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 4046
- Evidence Id
- 12604
- Core Evidence Id
- 12604
- Source Meta Analysis Id
- 4006
- Herb2 Meta Analysis Id
- HBMA004006
- Crd Id
- CRD42021225227
- Title
- Does reserpine really cause depression? A systematic review
- Review Question
- To evaluate the effects of the anti-hypertensive medication reserpine on depressive symptoms across human studies by synthesising the evidence from all studies assessing a reserpine-treated condition and an untreated condition in any human population.
- Study Type Included
- There is no restriction on the types of study design eligible for inclusion.
- Condition Being Studied
- Depression
- Participant
- Inclusion criteria: - Participants of any gender - Participants of any adult age - Adults not treated with reserpine and those treated with reserpine (either within or between subjects) Exclusion criteria: - Studies of children or adolescents (18 years of age) will be excluded, due to differing treatment mechanisms in young people.
- Animal
- Human Disease Modelled
- Intervention
- Reserpine is an anti-hypertensive medication which has been historically used as an early antipsychotic. Clinical efficacy of reserpine has been seen (Roy, P., 2018), however following reports of reserpine as a depressant, use of the drug fell. There is scepticism regarding the claim that reserpine causes depression, which require further exploration (Healy, D., & Savage, M., 1998). To clarify this controversy, we will be looking at all available studies assessing the effect of reserpine on symptoms of depression in any adult human sample.
- Comparator Control
- Any data of those untreated with reserpine (usually a pre-treatment measure of the outcome, to be compared with subsequent measurement after treatment; alternatively, an untreated group to be compared with a treated group).
- Main Outcome
- Differences in depressive symptoms between the reserpine-untreated and reserpine-treated conditions (e.g., the pre- and post- treatment time points or between treated/untreated participants.) Any assessment that captures depression will be selected. Clinician-rated measures will be prioritised over patient-rated, along with prioritising validated measures of depression – with particular focus on the gold standards (MADRS; Montgomery & Asberg, 1977 or HAMD; Hamilton, 1960). Measures of effect Severity in untreated versus treated conditions will be compared using a standardised effect size (cohen’s d or hedges’ g).
- Outcome Measure
- Additional Outcome
- 1. Extent of adherence to reserpine and any comparison interventions (e.g. trial dropout, non-completion or alternative compliance data). 2. Extent of tolerability for reserpine (e.g., side-effects reported, particularly those associated with mood or psychiatric symptoms, discontinuation as a result of side effects or data from a questionnaire assessing side effects or beliefs about treatment). 3. Effects of reserpine on other symptoms associated with depression e.g. anxiety, suicide, or other individual symptoms of depression Measures of effect Relative risk or odds ratio will be used for binary outcomes. Continuous variables will be treated the same as main outcome.
- Study Method
- Narrative synthesis, Systematic review
- Keyword
- Depression; Humans; Reserpine
- Contact
- Rahila Javed [email protected]
- Organisational Affiliation
- Institute of Psychology, Psychiatry, Neuroscience, King's College London.
- Funding Source
- This paper represents independent research funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. The funder had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- England
- Review Stage
- Review Ongoing
- First Submission Date
- 2021-01-27
- Registration Date
- 2021-01-28
- Anticipated Start Date
- 2021-01-01
- Anticipated Completion Date
- 2021-08-18
- Title Cn
- 利血平是否确实导致抑郁？一项系统评价
- Title En
- Does reserpine really cause depression? A systematic review
- Bilingual Status
- complete